Legal action against individuals for personal drug importation: what the record shows

If you are considering personal importation of prescription medication, you are likely worried about a specific question that commercial sites tend to either dramatize or dodge: will I be prosecuted? This page addresses that question honestly, using primary federal sources only.

What does federal law say about enforcement against individuals?

Two primary-source provisions specifically address federal enforcement against individual personal importers. Neither legalizes importation; both narrow how the federal government may act.

21 U.S.C. § 381(g) — a restriction on FDA warning notices

The warning-notice provision, codified at 21 U.S.C. § 381(g), restricts the FDA’s ability to send warning notices to individual personal importers. With respect to a prescription drug being imported, the Secretary — in the case of an individual who is not in the business of such importations — may not send a warning notice unless the notice specifies the determination underlying it and states the underlying reasons.[1] The practical effect is procedural: the FDA cannot send a generic enforcement letter to an individual personal importer without identifying the specific basis. This is a due-process restriction on the agency’s communications, not an authorization to import.

21 U.S.C. § 384(j) — a congressional enforcement-priority declaration that is not in effect

A separate provision, 21 U.S.C. § 384(j), contains a congressional declaration that in enforcing the importation prohibition against individuals, the Secretary should focus enforcement on cases where an individual’s importation poses a significant threat to public health, and should exercise discretion to permit personal-use importations that do not appear to present an unreasonable risk.[2] Two cautions about this provision, both important. First, it is phrased as what the Secretary “should” do — a stated priority, not a grant of permission to the patient. Second, and decisively: § 384(j) is part of Section 804 of the Federal Food, Drug, and Cosmetic Act, which by its own terms becomes effective only after the Secretary issues a certification to Congress that has not been made for the personal-importation provisions. As explained on the framework page, the personal-importation provisions of Section 804 are not in legal effect. This declaration therefore describes a congressional policy preference, not an operative legal restriction a patient can rely on.

The CBP appropriations rider

Separately, successive Department of Homeland Security appropriations acts have carried a rider — renewed across fiscal years since the mid-2000s — restricting the use of CBP appropriated funds to prevent an individual not in the business of importing from bringing in a personal-use quantity of a prescription drug from Canada that complies with the Federal Food, Drug, and Cosmetic Act, limited to a personally-carried supply not exceeding 90 days and excluding controlled substances.[3] The qualifications do significant work, and narrow the rider to a small set of cases:

• CBP only — it restricts CBP funds, not FDA authority.
• Canada only — imports from other countries are outside it.
• Personally carried only — mailed and courier shipments are outside it.
• FFDCA-compliant only — the drug must comply with U.S. labeling and approval requirements, which, as the Congressional Research Service has observed, imported drugs in almost all cases do not.[4]
• Non-controlled only, and non-commercial only, and 90-day supply maximum.

What the rider accomplishes in practice is narrow: a U.S. resident carrying a 90-day supply of an FDA-approved, U.S.-labeled, non-controlled drug across the Canadian border for personal use cannot have it seized using CBP appropriated funds. For mailed imports from other countries — the most common cost-driven pattern — it provides no protection.

What the documented enforcement record contains

Federal criminal prosecutions for prescription drug importation are real and ongoing. Available Department of Justice and FDA Office of Criminal Investigations records show enforcement directed at commercial actors, in three recurring patterns.

Commercial diversion schemes

In one 2023 matter, a South Florida resident was sentenced to 87 months in federal prison for participating in a scheme distributing adulterated and misbranded prescription medications into the U.S. wholesale chain.[5] The prosecution targeted participation in a commercial fraud operation — not personal-use importation.

Online pharmacy operators selling controlled substances

In a 2022 matter, the operator of an internet operation that sold controlled and non-controlled prescription drugs without valid prescriptions — including a large volume of a Schedule III controlled substance — was sentenced to 15 months and ordered to forfeit proceeds.[6] The prosecution targeted a commercial seller, not an individual importer.

Importation-facilitator storefronts

In 2018, federal action targeted Central Florida storefronts that helped customers place foreign-pharmacy orders, warning the owners they were operating illegally.[7] The action targeted the storefronts as commercial facilitators; the individual customers were not the subjects of the enforcement action.

What the documented record does not contain

The argument here is an absence-of-evidence argument: reviews of FDA Office of Criminal Investigations press releases, DOJ press releases, FDA warning letters, and legal literature have not identified publicly documented federal criminal prosecutions of individual U.S. patients for personally importing non-controlled prescription drugs for their own use over the past two decades. This is a claim about what published records show — not a claim that no such prosecution has ever occurred or could occur. Several things follow:

• This is not a legal safe harbor. Federal law continues to prohibit unauthorized importation of unapproved drugs, and the agencies retain full authority to act. Past enforcement patterns do not bind future choices.
• It is consistent with the FDA’s stated posture. The agency’s manual directs enforcement at commercial shippers, health-fraud products, and Import-Alert shipments — matching who actually appears in the prosecution record.[8]
• It does not extend to controlled substances, which are governed by a separate framework with far higher exposure (see controlled substances); to commercial activity; to state pharmacy board action; or to civil and administrative consequences — CBP can seize a shipment, and the FDA can administratively destroy a mailed shipment valued at $2,500 or less.[9]

What this means for you

Three implications follow. Calibrate the legal exposure honestly — it is neither zero nor the criminal-prosecution risk some cautionary framings imply; the documented reality is a real probability of seizure or destruction, a documented absence of federal criminal prosecutions of individual non-controlled personal importers, and a sharply higher risk profile if the drug is a controlled substance or the conduct is commercial. Understand the limits of the “no documented prosecutions” point — it is a federal-criminal observation only; CBP seizures, FDA destruction of mailed shipments under $2,500, and state board action are separate and real. Speak with your prescriber — the legal record says nothing about clinical risk, which exists regardless of where medication originates (see why your prescriber must know).

This page does not provide legal advice. It is general information about federal enforcement posture, drawn from primary statutory text, the FDA’s published documents, and the documented federal enforcement record. Patients with specific legal questions should consult a U.S.-licensed attorney with experience in FDA regulatory or healthcare law.

Editorial methodology

This article is based on publicly available federal enforcement materials, statutory text, agency guidance, and legal analyses reviewed through June 8, 2026. It describes the documented public record available to the authors at the time of review. It does not assert that no contrary example exists, that future enforcement will follow historical patterns, or that any particular importation is lawful.